Rahmati-Dehkordi Fatemeh, Birang Nafiseh, Jalalian Mohammad Naser, Tamtaji Zeinab, Dadgostar Ehsan, Aschner Michael, Shafiee Ardestani Mehdi, Jafarpour Hamed, Mirzaei Hamed, Nabavizadeh Fatemeh, Tamtaji Omid Reza
Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb;398(2):1081-1097. doi: 10.1007/s00210-024-03397-w. Epub 2024 Sep 3.
Neuropsychiatric disorders present a global challenge to public health. Mechanisms associated with neuropsychiatric disorders etiology include apoptosis, oxidative stress, and neuroinflammation. Tumor necrosis factor alpha, an inflammatory cytokine, mediates pathophysiology of neuropsychiatric disorders. Therefore, its inhibition by infliximab might afford a valuable target for intervention. Infliximab is commonly used to treat inflammatory diseases, including ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Recently, it has been shown that infliximab improves cognitive dysfunction, depression, anxiety, and life quality. Here, we review contemporary knowledge supporting the need to further characterize infliximab as a potential treatment for neuropsychiatric disorders.
神经精神疾病对全球公共卫生构成挑战。与神经精神疾病病因相关的机制包括细胞凋亡、氧化应激和神经炎症。肿瘤坏死因子α作为一种炎性细胞因子，介导神经精神疾病的病理生理过程。因此，英夫利昔单抗对其的抑制作用可能成为一个有价值的干预靶点。英夫利昔单抗常用于治疗炎性疾病，包括溃疡性结肠炎、克罗恩病和类风湿关节炎。最近有研究表明，英夫利昔单抗可改善认知功能障碍、抑郁、焦虑及生活质量。在此，我们综述了当代相关知识，以支持进一步将英夫利昔单抗作为神经精神疾病潜在治疗方法进行深入研究的必要性。
